Q-omics provides the consensus-scored LGALSL profile across patient tissues and cancer cell-line models. LGALSL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LGALSL is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, LGALSL protein abundance shows 29,111 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUAD, and GBM as cancer lineages where LGALSL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LGALSL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LGALSL survival associations across molecular data types. LGALSL RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LGALSL RNA expression–survival associations across cancer types. High LGALSL expression shows unfavorable associations in UVM, BLCA, LAML and LGG, but favorable associations in KIRC and OV. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LGALSL RNA expression.
This table summarizes LGALSL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LGALSL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LGALSL shows lower tumor expression in LUAD, KICH, COAD and THCA and higher tumor expression in LIHC and KIRC. The LUAD box plot shows higher LGALSL RNA expression in normal versus tumor tissue (log2 FC = −2.304, t-test p < 0.001).
This table shows molecular features associated with LGALSL in patient tissues and cancer cell lines. In patient samples, LGALSL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LGALSL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BONE.
